Sildalis: A Dual-Action Therapy for Erectile Dysfunction
Sildalis
| Product dosage: 120mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 10 | $5.00 | $50.00 (0%) | 🛒 Add to cart |
| 20 | $3.00 | $100.00 $60.00 (40%) | 🛒 Add to cart |
| 30 | $2.67 | $150.00 $80.00 (47%) | 🛒 Add to cart |
| 60 | $1.67 | $300.00 $100.00 (67%) | 🛒 Add to cart |
| 90 | $1.56 | $450.00 $140.00 (69%) | 🛒 Add to cart |
| 120 | $1.42 | $600.00 $170.00 (72%) | 🛒 Add to cart |
| 180 | $1.22 | $900.00 $220.00 (76%) | 🛒 Add to cart |
| 270 | $1.00 | $1350.00 $270.00 (80%) | 🛒 Add to cart |
| 360 | $0.94
Best per pill | $1800.00 $340.00 (81%) | 🛒 Add to cart |
Synonyms | |||
Similar products
Sildalis represents a significant advancement in the pharmacological management of erectile dysfunction (ED), combining two well-established active compounds into a single, potent formulation. This medication is specifically engineered to address the multifaceted physiological challenges associated with achieving and maintaining an erection sufficient for satisfactory sexual performance. By leveraging a synergistic mechanism of action, Sildalis offers a robust therapeutic option for men for whom monotherapy may provide suboptimal results. Its design focuses on enhancing blood flow to the penile tissues while simultaneously modulating the psychological and neurological components of sexual arousal. This comprehensive approach positions Sildalis as a first-line combination therapy under appropriate medical guidance.
Features
- Combination formula containing Tadalafil and Sildenafil Citrate.
- Dual-mechanism PDE5 inhibition for comprehensive erectile support.
- Standardized dosage strengths for precise therapeutic management.
- Oral tablet formulation for ease of administration.
- Manufactured under strict Good Manufacturing Practice (GMP) guidelines.
Benefits
- Enhanced Efficacy: The dual-action mechanism provides a more robust and reliable therapeutic effect compared to single-agent therapies for many patients.
- Improved Spontaneity: The extended duration of action from one component allows for a longer window of opportunity for sexual activity, reducing time-sensitive pressure.
- Increased Responsiveness: Works in response to sexual stimulation, supporting a natural sexual experience rather than causing an automatic erection.
- Psychological Confidence: Reliable performance can significantly reduce anxiety related to sexual performance, which is often a compounding factor in ED.
- Streamlined Treatment: A single tablet regimen improves adherence compared to managing multiple medications or timing different doses.
Common use
Sildalis is prescribed for the treatment of erectile dysfunction (ED) in adult males. It is used to facilitate the achievement and maintenance of an erection sufficient for sexual intercourse. It is important to understand that this is not an aphrodisiac; sexual stimulation is required for the medication to be effective. Its use is typically considered when a patient has demonstrated an inadequate response to a maximum tolerated dose of a single PDE5 inhibitor, or when the unique pharmacokinetic profile of the combination is deemed clinically advantageous by a prescribing physician.
Dosage and direction
The dosage of Sildalis must be determined by a healthcare professional based on the patient’s health status, tolerance, and treatment response. The typical recommended dose is one tablet taken orally approximately 30-60 minutes before anticipated sexual activity. It can be taken with or without food; however, a high-fat meal may delay the onset of action. The medication should not be taken more than once in a 24-hour period. It is crucial to follow the prescribed dosage exactly and not to adjust it without consulting a doctor.
Precautions
- Prior to initiation, a thorough medical history and cardiovascular assessment are mandatory due to the potential cardiac strain of sexual activity.
- Use with caution in patients with anatomical deformation of the penis (e.g., angulation, cavernosal fibrosis, Peyronie’s disease).
- Caution is advised in patients with conditions that may predispose them to priapism (e.g., sickle cell anemia, multiple myeloma, leukemia).
- Patients with severe renal or hepatic impairment should use this medication with extreme caution, and dosage adjustment is likely necessary.
- This medication offers no protection against sexually transmitted diseases.
- Non-arteritic anterior ischemic optic neuropathy (NAION) has been reported post-marketing; discontinue use immediately and seek medical attention if sudden vision loss occurs.
Contraindications
Sildalis is strictly contraindicated in the following scenarios:
- Concomitant use of any form of organic nitrates (e.g., nitroglycerin, isosorbide mononitrate/dinitrate) or nitric oxide donors. This combination can cause a severe, life-threatening drop in blood pressure.
- History of a hypersensitivity reaction to Tadalafil, Sildenafil, or any of the inactive ingredients in the formulation.
- Patients with severe cardiovascular instability, including those with recent myocardial infarction, stroke, or life-threatening arrhythmia within the last 6 months.
- Patients with uncontrolled hypertension or hypotension.
- Concurrent use with potent CYP3A4 inhibitors (e.g., ritonavir, ketoconazole, itraconazole) in certain populations.
Possible side effect
As with all potent pharmacological agents, Sildalis may cause side effects. Not all patients will experience them.
- Very Common (>10%): Headache, flushing.
- Common (1-10%): Dyspepsia (indigestion), nasal congestion, back pain, myalgia (muscle pain), dizziness, visual disturbances (e.g., blurred vision, cyanopsia - seeing a blue tinge).
- Uncommon (0.1-1%): Palpitations, tachycardia, hypotension, nausea, vomiting, rash.
- Rare (<0.1%): Priapism (a prolonged and painful erection lasting more than 4 hours), sudden hearing loss, syncope (fainting), NAION. Patients should be advised to seek immediate medical attention for erections lasting more than 4 hours or for any sudden changes in vision or hearing.
Drug interaction
Sildalis has a significant and potentially dangerous interaction profile. Key interactions include:
- Nitrates: Absolute contraindication. Concomitant use can cause profound hypotension, shock, or death.
- Alpha-blockers (e.g., doxazosin, tamsulosin): May potentiate the blood-pressure-lowering effects, leading to symptomatic hypotension (dizziness, lightheadedness, fainting). A separation in dosing time may be required.
- Potent CYP3A4 Inhibitors (e.g., ketoconazole, ritonavir, clarithromycin): Can significantly increase the plasma concentration of Sildalis, elevating the risk of adverse effects. Dose adjustment is mandatory, or use should be avoided.
- Antihypertensives: May have an additive effect on blood pressure lowering.
- Alcohol: Excessive consumption can increase the risk of orthostatic hypotension, dizziness, and increased heart rate.
Missed dose
Sildalis is not intended for chronic daily dosing but is taken on an as-needed basis. Therefore, the concept of a “missed dose” does not apply in the traditional sense. If a dose is not taken prior to sexual activity, it should simply be taken at the next appropriate opportunity, ensuring that at least 24 hours have passed since any previous dose. Do not take a double dose to make up for a missed one.
Overdose
In the event of a suspected overdose, medical attention should be sought immediately. The most likely manifestations of an overdose would be an extension of the drug’s known vasodilatory effects, including severe headache, profound hypotension, reflex tachycardia, dizziness, fainting, and potentially priapism. Standard supportive measures should be employed, including maintaining cardiovascular stability. Hemodialysis is not expected to accelerate clearance significantly due to high protein binding.
Storage
- Store at room temperature (15°-30°C or 59°-86°F).
- Protect from light and moisture.
- Keep in the original container to protect from light and humidity.
- Keep out of reach of children and pets.
- Do not use after the expiration date printed on the packaging.
Disclaimer
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any new treatment. Never disregard professional medical advice or delay in seeking it because of something you have read here. The information provided has been compiled from various sources and may not be exhaustive or fully updated.
Reviews
- “After struggling with the effectiveness of single-agent treatments, my urologist suggested Sildalis. The difference has been remarkable. The combination provides a reliability and duration I hadn’t experienced before, which has greatly reduced my performance anxiety.” – M.C., 54
- “The clinical data on dual PDE5 inhibition is compelling. In my practice, I reserve Sildalis for patients who are non-responders to monotherapy. The results have been consistently positive, with improved IIEF scores and high patient satisfaction, though it requires careful patient selection and monitoring.” – Dr. A. Sharma, Urologist
- “It works effectively, but the side effects were pronounced for me initially—significant flushing and a headache. These subsided after the first few uses, but it’s something to be aware of. The trade-off for efficacy was worth it in my case.” – J.L., 61
- “The convenience of a single tablet with a long duration of action is its biggest advantage from a patient compliance perspective. It removes the guesswork and timing anxiety associated with shorter-acting agents.” – Clinical Pharmacist Review